Valuation : BenevolentAI S.A.

Market Cap 8.34M 11.26M 9.71M 9.15M 15.58M 1.06B 15.7M 108M 42.04M 544M 42.28M 41.35M 1.79B P/E 2023
-1.75x
P/E 2024 -
Enterprise Value -18.83M -25.43M -21.94M -20.67M -35.2M -2.4B -35.46M -245M -94.96M -1.23B -95.49M -93.41M -4.03B EV / Sales 2023
5.72x
EV / Sales 2024 2.15x
Free-Float
59.54%
Yield 2023 *
-
Yield 2024 -
3 years 0.07
Extreme 0.07
2.66
5 years 0.07
Extreme 0.07
10
10 years 0.07
Extreme 0.07
10
Manager TitleAgeSince
Chief Operating Officer 50 2014-01-31
Director of Finance/CFO - 2024-10-15
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 70 2020-06-30
Chairman 70 2024-05-01
Director/Board Member 58 2013-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/24 Buy

Director

10,000 0.0070%
2/9/24 Buy

Director

2,066 0.0014%
2/9/24 Buy

Director

20,000 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
-14.74%-.--%-.--%-92.29% 11.59M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-2.88%+429.29%+521.04% 44.98B
+2.13%+0.89%+43.59%+19.44% 42.52B
+0.87%-3.73%+8.96%+76.62% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+6.82% - - 17.09B
+1.68%-4.20%+25.28%+123.70% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.13%+80.94%+42.82% 13.48B
Average -0.25%-5.14%+68.60%+87.41% 27.22B
Weighted average by Cap. +1.01%-2.25%+93.36%+128.98%

Financials

2023 2024
Net sales 7.33M 9.9M 8.54M 8.05M 13.7M 935M 13.81M 95.26M 36.97M 478M 37.18M 36.37M 1.57B 5.24M 7.08M 6.11M 5.75M 9.8M 669M 9.87M 68.11M 26.43M 342M 26.58M 26M 1.12B
Net income -63.32M -85.51M -73.77M -69.49M -118M -8.08B -119M -823M -319M -4.13B -321M -314M -13.57B -71.82M -97M -83.68M -78.83M -134M -9.16B -135M -933M -362M -4.68B -364M -356M -15.39B
Net Debt -68.16M -92.05M -79.41M -74.81M -127M -8.7B -128M -886M -344M -4.45B -346M -338M -14.6B -27.17M -36.69M -31.65M -29.82M -50.78M -3.47B -51.16M -353M -137M -1.77B -138M -135M -5.82B
Logo BenevolentAI S.A.
BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
Employees
173